Muscle wasting associated with pathologic change is a risk factor for the exacerbation of joint swelling in collagen-induced arthritis in cynomolgus monkeys

BMC Musculoskeletal Disorders

Kazuhiro Abeyama³  Atsuro Miyata²  Ryoichi Nagata⁶  Koichiro Fukuzaki⁶  Yoshihisa Umekita⁵  Takako Yoshioka⁴  Hayato Kasai⁶  Itsuro Higuchi¹  Takaharu Nagaoka⁶  Naoto Horai⁶ 

[1] Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Department of Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Department of Radiology, Morizono Hospital, 19-38 Oshoji-cho, Satsumasendai, Kagoshima 895-0076, Japan;Department of Tumor Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Division of Organ Pathology, Faculty of Medicine, Tottori University, 86 Nishi-machi, Yonago, Tottori 683-8503, Japan;Shin Nippon Biomedical Laboratories, Ltd. Drug Safety Research Laboratories (SNBL DSR), 2438 Miyanoura, Kagoshima 891-1394, Japan

关键词: Muscle;    Histopathology;    Steroid;    Hypoxia;    Muscle wasting;    Cynomolgus monkey;    Rheumatoid arthritis;    Collagen-induced arthritis;   

Others  :  1130370
DOI  :  10.1186/1471-2474-14-205

 received in 2013-01-16, accepted in 2013-07-05,  发布年份 2013

【 摘 要 】

Background

Not only joint destruction but also muscle wasting due to rheumatoid cachexia has been problem in terms of quality of life of patients with rheumatoid arthritis (RA). In the present study, we performed histopathological examination and assessed relationships between characteristic parameters relating to muscle and joint swelling in a collagen-induced arthritis (CIA) model using cynomolgus monkeys (CMs).

Methods

Female CMs were used and CIA was induced by twice immunizations using bovine type II collagen with Freund’s complete adjuvant. Arthritis level was evaluated from the degree of swelling at the peripheral joints of the fore and hind limbs. Food consumption, body weight, and serum biochemical parameters were measured sequentially. Five or 6 animals per time point were sacrificed at 2, 3, 5 and 9 weeks after the first immunization to obtain quadriceps femoris specimens for histopathology. Pimonidazole hydrochloride was intravenously administered to determine tissue hypoxia in skeletal muscle.

Results

Gradual joint swelling was observed and the maximum arthritis score was noted at Week 5. In histopathology, necrosis of muscle fiber in the quadriceps femoris was observed only at Week 2 and the most significant findings such as degeneration, atrophy, and regeneration of muscle fiber were mainly observed at Week 5. Food consumption was decreased up to Week 4 but recovered thereafter. Body weight decreased up to Week 5 and did not completely recover thereafter. A biphasic increase in serum cortisol was also observed at Weeks 2 and 5. Histopathology showed that muscle lesions were mainly composed of degeneration and atrophy of the muscle fibers, and ATPase staining revealed that the changes were more pronounced in type II muscle fiber than type I muscle fiber. In the pimonidazole experiment, mosaic pattern in skeletal muscle was demonstrated in the intact animal, but not the CIA animal. Increased arthritis score was accompanied by a decrease in serum creatinine, a marker that reflects muscle mass.

Conclusions

Muscle wasting might exacerbate joint swelling in a collagen-induced arthritis model of cynomolgus monkeys.

【 授权许可】

   
2013 Horai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M: Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 2008, 31:1159-1163. [Pubmed]
• [2]Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki : Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol 2008, 84:262-270. [Pubmed]
• [3]Saito M, Yoshigae Y, Nakayama J, Ogawa Y, Ohtsuki M, Kurihara A, Ikeda T: Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys. Life Sci 2007, 80:2005-2014. [Pubmed]
• [4]Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM: Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005, 7:1-20. [Pubmed]
• [5]Yang C, Robbins PD: Immunosuppressive exosomes: a new approach for treating arthritis. Int J Rheumatol 2012, 2012:8. 573528. [Pubmed]
• [6]Ogasawara A, Utoh M, Nii K, Ueda A, Yoshikawa T, Kume T, Fukuzaki K: Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos 2009, 37:122-128. [Pubmed]
• [7]Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, Booth-Genthe C: Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 2006, 34:1703-1712. [Pubmed]
• [8]Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH: In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 2006, 34:1546-1555. [Pubmed]
• [9]Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872. [Pubmed]
• [10]Fujii Y, Hirayama T, Ohtake H, Ono N, Inoue T, Sakurai T, Takayama T, Matsumoto K, Tsukahara N, Hidano S, Harima N, Nakazawa K, Igarashi Y, Goitsuka R: Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J Immunol 2012, 188:206-215. [Pubmed]
• [11]Sato T, Fujii R, Konomi K, Yagishita N, Aratani S, Araya N, Aono H, Yudoh K, Suzuki N, Beppu M, Yamano Y, Nishioka K, Nakajima T: Overexpression of SPACIA1/SAAL1, a newly identified gene that is involved in synoviocyte proliferation, accelerates the progression of synovitis in mice and humans. Arthritis Rheum 2011, 63:3833-3842. [Pubmed]
• [12]Zhang W, Wang B, Wang F, Zhang J, Yu J: CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol 2012, 50:150-159. [Pubmed]
• [13]Chou LW, Wang J, Chang PL, Hsieh YL: Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Res Ther 2011, 13:R90. [Pubmed] BioMed Central Full Text
• [14]Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L: Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011, 17:1039-1044. [Pubmed]
• [15]Abreu JR, Krausz S, Dontje W, Grabiec AM, de Launay D, Nolte MA, Tak PP, Reedquist KA: Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Rheum 2010, 62:3289-3299. [Pubmed]
• [16]Wierda D, Smith HW, Zwickl CM: Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001, 158:71-74. [Pubmed]
• [17]Vierboom MP, Breedveld E, Kondova I, t Hart BA: Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther 2010, 12:R200. [Pubmed] BioMed Central Full Text
• [18]Chapman K, Pullen N, Graham M, Ragan I: Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007, 6:120-126. [Pubmed]
• [19]Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE: Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110:420-424. [Pubmed]
• [20]Bisoendial RJ, Stroes ES, Tak PP: Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2011, 17:21-26. [Pubmed]
• [21]Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994, 93:2379-2386. [Pubmed]
• [22]Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD: Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010, 6:445-451. [Pubmed]
• [23]Walsmith J, Roubenoff R: Cachexia in rheumatoid arthritis. Int J Cardiol 2002, 85:89-99. [Pubmed]
• [24]Plasqui G: The role of physical activity in rheumatoid arthritis. Physiol Behav 2008, 94:270-275. [Pubmed]
• [25]Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544. [Pubmed]
• [26]Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1alpha and Ets-1 co localize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004, 50:291-296. [Pubmed]
• [27]Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008, 58:2675-2685. [Pubmed]
• [28]Hasselgren PO: Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999, 2:201-205. [Pubmed]
• [29]Menconi M, Fareed M, O'Neal P, Poylin V, Wei W, Hasselgren PO: Role of glucocorticoids in the molecular regulation of muscle wasting. Crit Care Med 2007, 35:S602-S608. [Pubmed]
• [30]Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197:1-10. [Pubmed]
• [31]Summers GD, Deighton CM, Rennie MJ, Booth AH: Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 2008, 47:1124-1131. [Pubmed]
• [32]Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, Abad LW, Lundgren NT, Roubenoff R: Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum 2002, 46:2574-2577. [Pubmed]
• [33]Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004, 43:1219-1223. [Pubmed]
• [34]Magyar E, Talerman A, Mohacsy J, Wouters HW, de Bruijn WC: Muscle change in rheumatoid arthritis. A review of the literature with a study of 100 cases. Virchows Arch A Path Anat Histol 1977, 373:267-278. [Pubmed]
• [35]Saini A, Al-Shanti N, Stewart CE: Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 2006, 17:475-486. [Pubmed]
• [36]Penner G, Gang G, Sun X, Wray C, Hasselgren PO: C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am J Physiol Regul Integr Comp Physiol 2002, 282:R439-R444. [Pubmed]
• [37]Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959-3964. [Pubmed]
• [38]Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307. [Pubmed]
• [39]Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697. [Pubmed]
• [40]Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732. [Pubmed]
• [41]Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143. [Pubmed]
• [42]Hartog A, Hulsman J, Garssen J: Locomotion and muscle mass measures in a murine model of collagen-induced arthritis. BMC Musculoskelet Disord 2009, 10:59. [Pubmed] BioMed Central Full Text